AstraZeneca’s U.S. Pricing Deal and Virginia Plant Fail to Lift Stock
AstraZeneca's shares remained flat despite two significant developments: a forthcoming drug pricing agreement with the TRUMP administration and the groundbreaking of a $4.5 billion Virginia facility. The Cambridge-based pharmaceutical giant will sell select medications at reduced 'most-favored-nation' prices, mirroring a recent Pfizer deal, though specifics remain undisclosed.
The Virginia plant, part of a $50 billion U.S. investment strategy, will become AstraZeneca's largest global production site. Market reaction was muted, with AZN shares trading around $84 amid broader pharmaceutical sector pressures. The pricing arrangement follows Pfizer's three-year tariff exemption secured last month, signaling continued WHITE House focus on healthcare costs.
